These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37795433)

  • 21. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
    Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
    Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer.
    Brown BP; Zhang YK; Kim S; Finneran P; Yan Y; Du Z; Kim J; Hartzler AL; LeNoue-Newton ML; Smith AW; Meiler J; Lovly CM
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2206588119. PubMed ID: 35867821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
    Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
    Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon
    Tan J; Hu C; Deng P; Wan R; Cao L; Li M; Yang H; Gu Q; An J; Jiang J
    Front Oncol; 2021; 11():646577. PubMed ID: 34513661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
    Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
    Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationship between mutations of epidermal growth factor receptor gene and clinicopathologic features of non-small cell lung cancers].
    Wang F; Fu S; Tang T; Deng L; Zhang X; Li YZ; Shao JY
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):664-6. PubMed ID: 22321543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic profiling reveals non-small cell lung cancer with common mutations of
    Bi X; Song P; Wang C; Zhang X; Liu C
    Transl Cancer Res; 2022 May; 11(5):1423-1428. PubMed ID: 35706785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
    Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
    Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [EGFR Mutations Detection in Non-small Cell Lung Cancer Tissues by Real-time PCR and DNA Sequencing.].
    Li Y; Liu H; Li Y; Wang Y; Wang J; Chen J; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2009 Dec; 12(12):1255-9. PubMed ID: 20723379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
    Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
    Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
    Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
    Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
    Zhou S; Hu X; Wang Y; Li J; Zhou L; Hao X; Liu Y; Shi Y
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):166-171. PubMed ID: 30311393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
    Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
    BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.